PF-00299804 as a Single Oral Agent in Untreated Adenocarcinoma of the Lung in Nonsmokers or Former Light Smokers

Article

This study will evaluate the safety and efficacy of PF-00299804, an oral PanHER inhibitor created by Pfizer, in patients with adenocarcinoma of the lung who are either nonsmokers or former light smokers.

Study Type: Interventional

Age/Sex Requirements: 18 years+ (None)

Sponsor: Pfizer

ClinicalTrials.gov Identifier: NCT00818441

Purpose: To evaluate the safety and efficacy of PF-00299804, an oral PanHER inhibitor created by Pfizer, in patients with adenocarcinoma of the lung who are either nonsmokers or former light smokers. The study defines nonsmokers as those who have smoked less than 100 cigarettes, cigars, or pipes in their lifetime, and former lightsmokers as those who have a less than 10-pack year history of smoking and have been nonsmokers for at least 15 years. The primary outcome measure will be progression-free survival at 4 months. Secondary outcome measures include best overall response, duration of response, overall survival, overall safety profile, patient reported outcomes of health, trough concentrations of PF-00299804, and EGFR and HER signaling pathways in blood and tissue at baseline and during the study.

Click here to learn more about this clinical trial.

Related Videos
Video 3 -  4 KOLs are featured in, "Collaborating with Specialists: Primary Care Clinician’s Evolving Role in HE Management"
Video 3 -  4 KOLs are featured in, "HE Experts on Symptoms, Risk Factors, Diagnosis Challenges, and Severity Grading"
Shauna Applin, ARNP, an expert on HIV
© 2024 MJH Life Sciences

All rights reserved.